Commercialization and Prototype Development

  • Elisa Kit Development – BioMark has successfully developed Elisa kits using antibodies generated at UBC’s Biomedical Research Centre by Dr. Schrader and his team. The kits were developed under CLSI specifications and are under key customer test site. Double blinded study was also designed to ensure the reliability of the test kits
  • Point Of Care System – Next generation IVD point of care system is being developed in Canada after monoclonal antibodies were successfully generated and cloned at BRC early April. BioMark will again involve all critical stakeholders in the design and testing of this kit which would be strategically positioned for the medical market.
  • SERs (Surface Enhanced Raman System) – Major advancements have been made by Dr. Rueven and Fraser at UVic in relation to the use of Raman system. Patents have been filed and more is expected this year. BioMark will be working with the scientific team at UVic along with an industrial partner to develop new generation of detection systems in the future. More information and update to follow on this initiative.
Share this post:

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
FSE: 20B

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.